Endothelial function of von Hippel-Lindau tumor suppressor gene: Control of fibroblast growth factor receptor signaling

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4649-4657

  Champion, Kristen J ^a   Guinea, Maria ^a   Dammai, Vincent ^a   Hsu, Tien ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ETS 1; VON HIPPEL LINDAU PROTEIN; ETS1 PROTEIN, HUMAN; FGFR2 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HIF1A PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VHL PROTEIN, HUMAN; VHLH PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL MOTILITY; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HETEROZYGOSITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; ANIMAL; BIOTINYLATION; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; MOUSE MUTANT; NEWBORN; PHYSIOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

ANIMALS; BIOTINYLATION; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; INFANT, NEWBORN; KIDNEY; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKIN; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 49649105572     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6003     Document Type: Article

References (48)

1. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
2. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-67.
3. Kaelin WG, Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-82.
4. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999;96:12436-41.
5. Kamura T, Koepp DM, Conrad MN, et al. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 1999;284:657-61.
6. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 1999;13:1822-33.
7. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
8. Kamura T, Sato S, Iwai K, et al. Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000;97:10430-5.
9. Maynard MA, Ohh M. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. Am J Nephrol 2004;24:1-13.
10. Frew IJ, Krek W. Multitasking by pVHL in tumour suppression. Curr Opin Cell Biol 2007;19:685-90.
11. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
12. Kamada M, Suzuki K, Kato Y, Okuda H, Shuin T. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res 2001;61:4184-9.
13. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol 2003;5:64-70.
14. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
15. Davidowitz EJ, Schoenfeld AR, Burk RD. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol Cell Biol 2001;21:865-74.
16. Hsu T, Adereth Y, Kose N, Dammai V. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem 2006;281:12069-80.
17. Tang N, Mack F, Haase VH, Simon MC, Johnson RS. pVHL function is essential for endothelial extracellular matrix deposition. Mol Cell Biol 2006;26:2519-30.
18. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A 2001;98:1583-8.
19. Kleymenova E, Everitt JI, Pluta L, et al. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Carcinogenesis 2004;25:309-15.
20. Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
21. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003;63:6130-4.
22. Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. FASEB J 2002;16:1316-8.
23. Chintalapudi MR, Markiewicz M, Kose N, et al. Cyr61/CCN1 and CTGF/CCN2mediate the pro-angiogenic activity of VHL mutant renal carcinoma cells. Carcinogenesis 2008;29:696-703.
24. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A 1997;94:9102-7.
25. Richard L, Velasco P, Detmar M. A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res 1998;240:1-6.
26. Akis N, Madaio MP. Isolation, culture, and characterization of endothelial cells from mouse glomeruli. Kidney Int 2004;65:2223-7.
27. Gazzaniga S, Gonzalez L, Mantovani A, Vecchi A, Wainstok R. Isolation and molecular characterization of a mouse renal microvascular endothelial cell line. In vitro Cell Dev Biol Anim 2004;40:82-8.
28. Grant MB, Khaw PT, Schultz GS, Adams JL, Shimizu RW. Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-β on corneal cell chemotaxis. Invest Ophthalmol Vis Sci 1992;33:3292-301.
29. Liu X, Lin CS, Graziottin T, Resplande J, Lue TF. Vascular endothelial growth factor promotes proliferation and migration of cavernous smooth muscle cells. J Urol 2001;166:354-60.
30. Adryan B, Decker HJ, Papas TS, Hsu T. Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. Oncogene 2000;19:2803-11.
31. Dammai V, Adryan B, Lavenburg KR, Hsu T. Drosophila awd, the homolog of human nm23, regulates FGF receptor levels and functions synergistically with shi/dynamin during tracheal development. Genes Dev 2003;17:2812-24.
32. Hsouna A, Lawal HO, Izevbaye I, Hsu T, O'Donnell JM. Drosophila dopamine synthesis pathway genes regulate tracheal morphogenesis. Dev Biol 2007;308:30-43.
33. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301-14.
34. Wiley HS, Burke PM. Regulation of receptor tyrosine kinase signaling by endocytic trafficking. Traffic 2001;2:12-8.
35. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448-57.
36. Rabault B, Roussel MF, Quang CT, Ghysdael J. Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis. Oncogene 1996;13:877-81.
37. Wernert N, Raes MB, Lassalle P, et al. c-ets1 protooncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992;140:119-27.
38. Pourtier-Manzanedo A, Vercamer C, Van Belle E, et al. Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 2003;22:1795-806.
39. Yang BS, Hauser CA, Henkel G, et al. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol 1996;16:538-47.
40. Yordy JS, Muise-Helmericks RC. Signal transduction and the Ets family of transcription factors. Oncogene 2000;19:6503-13.
41. Welch RB. Von Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc 1970;68:367-424.
42. Chan CC, Vortmeyer AO, Chew EY, et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 1999;117:625-30.
43. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. HumPathol 1997;28:540-3.
44. Vortmeyer AO, Tran MG, Zeng W, et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol 2006;210:374-82.
45. Woodward ER, Wall K, Forsyth J, Macdonald F, Maher ER. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma. Brain 2007;130:836-42.
46. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
47. Reuter CW, Morgan MA, Grunwald V, et al. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol 2007;25:59-72.
48. Srinivasan R, Armstrong AJ, Dahut W, George DJ. Anti-angiogenic therapy in renal cell cancer. BJU Int 2007;99:1296-300.